Eledon Pharmaceuticals (ELDN) Operating Income (2013 - 2026)

Eledon Pharmaceuticals' Operating Income history runs 14 years deep, the most recent figure standing at -$21.2 million for Q1 2026.

• Quarterly Operating Income fell 17.91% year-over-year to -$21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$82.9 million (down 6.79% YoY) and the FY2024 annual result came in at -$70.6 million, down 64.13% from the prior year.
• Operating Income was -$21.2 million for Q1 2026 at Eledon Pharmaceuticals, down from -$19.1 million in the prior quarter.
• Across five years, Operating Income topped out at -$9.3 million in Q2 2022 and bottomed at -$58.7 million in Q4 2022.
• A 5-year average of -$17.8 million and a median of -$12.8 million in 2023 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2022 — Operating Income tumbled 525.34% — and 2023, when it jumped 82.38%.
• Eledon Pharmaceuticals' Operating Income stood at -$58.7 million in 2022, then jumped by 82.38% to -$10.3 million in 2023, then tumbled by 138.89% to -$24.7 million in 2024, then rose by 22.78% to -$19.1 million in 2025, then dropped by 11.07% to -$21.2 million in 2026.
• Business Quant data shows ELDN's Operating Income at -$21.2 million in Q1 2026, -$19.1 million in Q3 2025, and -$24.7 million in Q2 2025.